The therapeutic landscape for often chronic and impactful inflammatory skin conditions is currently rapidly developing. With the large number of new small molecule and monoclonal antibody therapies available and readily used in clinical routine and modern biomedical techniques available comes the opportunity to better understand disease mechanisms and working towards a targeted molecular therapeutic approach. Examples will include our current collaborative work in Psoriasis, HS and Atopic Dermatitis.